drugset / Trial / NCT00388505

Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis

NCT00388505

Phase 3 Completed 517 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

This study compares the safety of the tobramycin solution for inhalation with the tobramycin dry powder formulation, used with a simple inhaler

Timeline

Start
2006-02
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Tobramycin Small molecule 112 mg Inhaled
Subject Tobramycin Small molecule 300 mg Inhaled

Indications